April 3 (Reuters) - AstraZeneca PLC:
* US FDA APPROVES BYDUREON FOR USE WITH BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL
* 7 STUDY RESULTS SHOWED SIGNIFICANT HBA1C REDUCTION WHEN BYDUREON WAS ADDED TO INSULIN GLARGINE THERAPY VERSUS INSULIN GLARGINE ALONE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
